Shanghai, China

Xiaoping Zhao

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Xiaoping Zhao in Gene Therapy

Introduction

Xiaoping Zhao is a notable inventor based in Shanghai, China. He has made significant contributions to the field of gene therapy, particularly in the treatment of rare genetic disorders. His work focuses on developing innovative solutions that can improve the quality of life for patients suffering from genetic conditions.

Latest Patents

Xiaoping Zhao holds a patent for a recombinant adeno-associated viral vector designed for treating Bietti Crystalline Dystrophy (BCD). This patent includes a codon-optimized sequence encoding CYP4V2 linked to selected gene expression regulatory sequences. The invention aims to provide a therapeutic approach for individuals affected by BCD, showcasing Zhao's commitment to advancing medical science.

Career Highlights

Zhao is associated with Shanghai Vitalgen Biopharma Co., Ltd., where he collaborates with a team of dedicated professionals. His work at the company emphasizes the importance of innovative research in the biopharmaceutical sector. Zhao's expertise in gene therapy has positioned him as a key figure in the development of new treatment modalities.

Collaborations

Zhao has worked alongside talented colleagues, including Lu Guo and Yezheng Tao. Their collaborative efforts contribute to the advancement of research and development in gene therapy, fostering an environment of innovation and discovery.

Conclusion

Xiaoping Zhao's contributions to gene therapy, particularly through his patent for treating Bietti Crystalline Dystrophy, highlight his role as an influential inventor in the field. His work continues to inspire advancements in medical treatments and showcases the potential of innovative research in improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…